Intellia Therapeutics Inc buy Royal Bank of Canada
Start price
19.09.24
/
50%
€20.95
Target price
19.09.25
€48.55
Performance (%)
-12.12%
Price
26.09.24
€18.41
Summary
This prediction is currently active. The prediction for Intellia Therapeutics Inc disappoints with a performance of -12.12%. This prediction currently runs until 19.09.25. The prediction end date can be changed by Royal_Bank_of_Canada at any time. Royal_Bank_of_Canada has 50% into this predictionPerformance without dividends (%)
Name | 1w |
---|---|
Intellia Therapeutics Inc | -8.193% |
iShares Core DAX® | 0.936% |
iShares Nasdaq 100 | 3.064% |
iShares Nikkei 225® | 1.898% |
iShares S&P 500 | 1.653% |
Comments by Royal_Bank_of_Canada for this prediction
In the thread Intellia Therapeutics Inc diskutieren
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $54.00 price target on the stock.
Ratings data for NTLA provided by MarketBeat
Stopped prediction by Royal_Bank_of_Canada for Intellia Therapeutics Inc
Intellia Therapeutics Inc
Start price
Target price
Perf. (%)
€19.65
09.08.24
09.08.24
€49.44
09.08.25
09.08.25
-6.29%
26.09.24
26.09.24
Intellia Therapeutics Inc
Start price
Target price
Perf. (%)
€22.58
10.11.23
10.11.23
€65.49
10.11.24
10.11.24
-18.47%
26.09.24
26.09.24